Difficulties on the access to innovative targeted therapies for lung cancer in Spain

• Virginia Calvo ^[1] ; Carlos Camps ^[7] ; Enric Carcereny ^[2] ; Manuel Cobo ^[8] ; Manuel Dómine ^[3] ; María Rosario García Campelo ^[4] ; José Luis González Larriba ^[5] ; María Guirado ^[9] ; Florentino Hernando Trancho ^[5] ; Bartomeu Massutí ^[10] ; Ernest Nadal ^[2] ; Delvys Rodríguez Abreu ^[6] ; Alfredo Sánchez ^[11] ; Ivana Gabriela Sullivan ^[12] ; Mariano Provencio ^[1]
  1. [1] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  2. [2] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  3. [3] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  4. [4] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  5. [5] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  6. [6] Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Gran Canaria, España

     
  7. [7] Hospital General Universitario, Valencia, Spain
  8. [8] Hospital Regional Universitario, Málaga, Spain
  9. [9] Hospital General de Elche, Alicante, Spain
  10. [10] Hospital General Universitario Dr. Balmis, Alicante, Spain
  11. [11] Consorcio Hospital Provincial, Castellón, Spain
  12. [12] Hospital Santa Creu i Sant Pau, Barcelona, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 3, 2024, págs. 597-612
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Spanish Lung Cancer Group (SLCG) conducted a review to analyze the barriers to access to innovative targeted therapies for non-small cell lung cancer (NSCLC) in clinical practice in Spain.

    Methods Review all relevant content published on websites of European Commission, European Medicines Agency, and Spanish Agency of Medicines and Medical Products regarding the authorization and access to oncology treatments.

    Results More than 20 targeted therapies are available to treat different molecular alterations in patients with NSCLC. European Commission has approved treatments for genomic alterations involving the following genes: ALK, RET, ROS1, EGFR, BRAF, NTRK, KRAS, MET. However, the availability of these therapies in Spain is not complete, as innovative treatments are not reimbursed or funded late, with only five of these alterations currently covered by National Health System.

    Conclusion SLCG considers imperative to improve the access in Spain to innovative treatments for NSCLC to reduce inequity across European countries.